Ramipril in Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The present study is designed to evaluate the hypothesis that the Angiotensin-Converting Enzyme (ACE) inhibitor Ramipril improves vascular function and reduces markers of low-grade chronic inflammation and oxidative stress in patients with Rheumatoid Arthritis.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Zurich
• Collaborator: Sanofi
• Treatments: Ramipril

Criteria

Inclusion Criteria:

• patients with rheumatoid arthritis (4 out of 7 ARA criteria must be fulfilled to establish diagnosis) on stable background therapy for the last three months

• endothelial dysfunction (FMD < 4%, FMD:Flow-Mediated-Dilatation)

• non-smokers

Exclusion Criteria:

• previous myocardial infarction, coronary intervention or coronary surgery

• previous treatment with statins in the last 6 months

• previous treatment with ACE-inhibitors in the last 6 months

• uncontrolled hypertension SAP/DAP > 160/90 mmHg (SAP:Systolic Arterial Pressure, DAP:Diastolic Arterial Pressure)

• dyslipidemia (LDL-cholesterol > 4.9 mmol)

• normal CRP < 3 mg/l

• overweight BMI > 35kg/m2

• anaemia (hemoglobin < 10g/dl)

• kidney disease (creatinine > 150 umol/l)

• insulin-dependent diabetes mellitus

• congestive heart failure (> NYHA I)

• AV-Block>I

• pregnancy

• angio-edema

• malignancy or chronic infection

• drug abuse